Opinion

Video

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

Author(s):

Barbara Burtness, MD,Victoria M. Villaflor, MD

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Video content above is prompted by the following:

  • Is there a specific patient population that might benefit from this treatment?
  • Are there any external factors that may impact your treatment selection? Are you monitoring your patients for EBV titer?
Related Videos
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
2 KOLs are featured in this series.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
November 20th 2024

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

Versamune HPV in HPV16-Driven HNSCC ©stock.adobe.com
November 18th 2024

Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC

Rory Shallis, MD, assistant professor, medicine and hematology, Yale School of Medicine, Yale New Haven Health
September 26th 2024

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

David A. Braun, MD, PhD
November 9th 2024

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors